A Multicenter, Real-World, Observational Study: Genomic Landscape of Recurrence in Early-Stage (Clinical Stage IB-IIIA) Non-Small Cell Lung Cancer (NSCLC) Patients With EGFR Sensitizing Mutations After Adjuvant Osimertinib Treatment
This study was a multicenter, real-world observational study aimed at characterizing the genomic landscape of recurrence in patients with EGFR-sensitizing mutation-positive early-stage (clinical stage IB-IIIA) non-small cell lung cancer who received adjuvant osimertinib after surgery.
• Informed consent signed;
• Age ≥ 18 years;
• Histologically confirmed diagnosis of non-squamous non-small cell lung cancer;
• Patients with stage IB-IIIA (TNM 8#) NSCLC undergo confirmed radical R0 resection;
• Confirmed EGFR sensitive-mutations (exon 19 deletions, 21 L858R point mutations) prior to adjuvant osimertinib therapy;
• Recurrence after/on Osimertinib treatment according to RECIST 1.1;
• NGS gene test report (tumor or blood sample) at the time of recurrence;
• Receiving or not receiving neoadjuvant treatment before surgery.